期刊文献+

地特胰岛素联合阿卡波糖治疗血糖控制不佳的2型糖尿病患者的疗效 被引量:9

下载PDF
导出
摘要 控制高血糖是2型糖尿病(T2DM)治疗的基础,2003、2004、2006年我国大中城市门诊的调查表明仅有1/4的糖尿病(DM)患者糖化血红蛋白(HbA1c)达标(【6.5%)。本研究通过应用地特胰岛素(Det)联合阿卡波糖对比格列美脲联合阿卡波糖治疗血糖控制不佳的HbA1c】9%的T2DM,旨在探讨地特胰岛素作为基础胰岛素治疗T2DM的安全性、有效性及患者更好的依从性。1对象与方法 1.1研究对象选择2013年2至6月我院门诊就诊的T2DM患者36例,符合1999年糖尿病诊断标准,HbA1c】9%。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2014年第1期243-244,共2页 Chinese Journal of Gerontology
  • 相关文献

参考文献3

  • 1沈洁.地特胰岛素减少体重增加的可能机制与临床应用[J].中国糖尿病杂志,2010,18(3):238-240. 被引量:40
  • 2Nelson SE.Detemir as a once-daily basal insulin in type 2 diabetes[].Clinical Pharmacology.2011
  • 3Heise,Pieber.Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies[].Diabetes Obesity and Metabolism.2007

二级参考文献30

  • 1The Diabetes Control and Complications Research Group. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care, 1995,18 : 1415-1427.
  • 2UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998,352: 837 -853.
  • 3Yki-Jarvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab, 1997,82 : 4037-4043.
  • 4DCCT Research Group. Weight gain associated with intensive therapy in the diabetes control and complications trial. Diabetes Care, 1988,11 : 567-573.
  • 5Lin X, Taguchi A,Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and dia betes. J Clin Invest,2004,114:908-916.
  • 6Brunner GA, Sendhofer G, Wutte A, et al. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes, 2000,108 : 100-105.
  • 7Havelund S, Ribel U, Plum A, et al. The mechanism of protraction of insulin detemir, a long acting, acylated analogue of human insulin. Diabetes, 2004,53 : P462.
  • 8Hermansen K, Fontaine P, Kukolja KK, et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insu lins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia, 2004,47 : 622-629.
  • 9Raslovd K, Bogoev M, Raz I,et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract, 2004,66:193-201.
  • 10Haak T, Tiengo A, Draeger E,et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab, 2005,7 : 56-64.

共引文献39

同被引文献83

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部